介入治疗、三维适形放疗与氩氦刀治疗原发性肝癌的临床对比研究

目的将介入治疗、三维适形放疗和氩氦靶向冷冻消融治疗（氩氦刀治疗）三种方法结合比较,探讨不适合手术的原发性肝癌患者的较好治疗方案。方法将符合入选的116例原发性肝癌患者分为单纯介入组（A组）、介入＋三维适形放疗（3DCRT）组（B组）和介入＋氩氦刀组（C组）,比较三组的生存情况。结果 （1）A组、B组和C组1年生存率分别是14.98%、64%、85.71%;2年生存率分别是11.24%、32%、64.29%;3年生存率分别是0、0、32.14%。（2）三组间生存函数曲线差异有显著性（P〈0.05）,C组的生存曲线较A组和B组好。结论介入＋氩氦刀治疗能延长患者的生存时间,是不适合手术的原发性肝癌患者的较好治疗方案。

Clinical study on interventional therapy, three-dimensional conformal radiotherapy and targeted argon-helium cryoablation to primary hepatocellular carcinoma

Objective To find out a better therapy for unresectable HCC on the basis of the survival time by using three methods compared which were interventional therapy（IVT）,three-dimensional conformal radiotherapy（3D-CRT）,and targeted argon-helium cryoablation therapy（AHC）.Methods Total of 116 patients with unresectable HCC were divided into three groups which were IVT group（A group）,the IVT and 3D-CRT group（B group） and the IVT and AHC group（C group）.Results The survival rates for 1 year in A,B and C group were 14.98%,64.00%,85.71%,respectively.The corresponding survival rates for 2 year were 11.24%,32%,64.29%,respectively.The corresponding survival rates for 3 year were 0,0,32.14%,respectively.2.There were significantly different of survival functions in three groups（P0.05）.The survival curves of C group were better than that of A group and B group.Conclusion The IVT and ACH are a suitable therapy with unresectable HCC because of increased survival time of the patients.